查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2107819

艾森門格症候群治療市場：依藥物類型、通路和地區分類

Eisenmenger Syndrome Treatment Market, By Drug Type, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 257 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

艾森門格症候群治療市場預計在 2026 年達到 18 億美元，預計到 2033 年將達到 33.7 億美元。預計從 2026 年到 2033 年，該市場將以 9.4% 的複合年成長率成長。

報告範圍 報告詳情
基準年： 2025 2026年市場規模： 18億美元
歷史數據時期： 2020年至2024年 預測期： 2026年至2033年
2026年至2033年預測期間的複合年成長率： 9.40% 2033年市場規模預測： 33.7億美元

由於先天性心臟疾病(CHD) 的盛行率不斷上升、肺動脈高壓 (PAH)標靶治療的普及、早期診斷意識的提高以及獲得專業心臟護理設施的機會改善，預計市場將經歷顯著成長。

艾森門格症候群是嚴重的心臟疾病，是未經治療的先天性心臟併發症（例如心房中膈缺損症缺損 (VSD)、開放性動脈導管(PDA) 和房室導管缺損）的併發症。當長期異常血流導致進行性肺血管重塑時，就會發生這種疾病，進而導致肺動脈高壓、肺血管阻力增加和血流方向逆轉。這會導致血氧水平下降，並出現紫紺、呼吸困難、疲勞和運動能力下降等症狀。

艾森門格症候群的治療重點在於控制症狀、改善功能、延緩疾病進展和預防併發症。目前的治療方法包括支持性治療，以及針對肺動脈高壓的標靶治療，例如內皮素受體拮抗劑（ERA）、5型磷酸二酯酶（PDE-5）抑制劑和前列腺環素通路療法。隨著先進的肺動脈高壓（PAH）治療方法在臨床上的日益普及，以及心臟超音波圖、磁振造影（MRI）和基因檢測等診斷技術的進步，早期診斷和治療得以啟動。

此外，對罕見心血管疾病研發投入的增加進一步推動了市場成長。製藥公司正致力於開發治療肺動脈高壓和先天性心臟疾病併發症的先進療法。此外，成人先天性心臟疾病（ACHD）專科中心的普及、醫療基礎設施的改善以及推薦專科治療的最新臨床指南的製定，預計都將支持市場的長期擴張。

市場動態

艾森門格症候群治療市場的發展受到先天性心臟疾病負擔加重、標靶治療進步、診斷率提高以及對專業心血管護理需求不斷成長等因素的推動。

成長要素之一是全球先天性心臟疾病盛行率的上升。先天性心臟疾病是全球最常見的出生缺陷之一，未治療或延遲診斷的患者有發展為艾森門格症候群的風險。越來越多的先天性心臟疾病患者能夠存活至成年，這推動了對相關併發症進行終身監測和先進治療的需求。

推動市場成長的另一個關鍵因素是肺動脈高壓標靶治療的日益普及。內皮素受體拮抗劑、PDE-5抑制劑和前列腺環素療法已證實能有效改善艾森門格症候群患者的運動能力、降低肺血管阻力並控制症狀。聯合治療臨床經驗的累積正促使醫療專業人員根據患者的病情和疾病嚴重程度採取個別化的治療方案。

診斷技術的進步也促進了市場擴張。心臟超音波圖、心臟磁振造影、肺動脈高壓篩檢和基因檢測的準確性提高，使得先天性心臟疾病和肺血管病變的早期發現成為可能。早期診斷有助於及時干預，改善疾病管理效果，從而增加了對專門針對艾森門格症候群的治療方案的需求。

然而，市場面臨許多挑戰，例如治癒性治療選擇根治性、晚期肺動脈高壓（PAH）治療高成本以及疾病管理複雜。由於艾森門格症候群需要終身照護和監測，治療的可近性和經濟負擔仍然是人們關注的焦點，尤其是在發展中地區。此外，人們對這種罕見心血管疾病的認知不足會導致診斷和治療的延誤。

儘管面臨這些挑戰，但在預測期內，在對罕見疾病藥物研發投入增加、專業心臟護理中心擴張、醫療保健服務可及性提高以及靶向聯合治療的採用增加的推動下，預計將出現顯著的成長機會。

本次調查的主要特點

  • 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
  • 本研究深入分析了市場促進因素、限制因素、機會、治療趨勢、區域展望、臨床進展以及領先企業採取的競爭策略。
  • 本研究基於公司亮點、產品系列、重大發展、財務績效和策略，分析了艾森門格症候群治療市場的主要參與者。
  • 透過利用本報告中提出的見解，製藥公司、醫療保健提供者、投資者和其他相關人員可以就產品開發、市場擴張、合作夥伴關係和投資機會做出明智的決策。
  • 《艾森門格氏症治療市場報告》的目標對象包括製藥公司、生技公司、循環系統、呼吸科專家、醫院、專科醫療中心、醫療保健投資者、經銷商、監管機構和相關人員分析師等各類利害關係人。
  • 相關人員可以利用用於評估艾森門格症候群治療市場的系統分析框架和策略矩陣，從中獲益匪淺。

目錄

第1章：研究目標與前提條件

  • 分析目的
  • 先決條件
  • 簡稱

第2章 市場概覽

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

  • 促進因素
  • 抑制因子
  • 市場機遇
  • 影響分析
  • 市場趨勢
  • 近期上市和核准的藥品
  • 監管趨勢
  • 流行病學
  • PEST分析
  • 收購與合作情景

第4章 全球艾森門格症候群治療市場：依藥物類型分類，2021-2033年

  • 抗心律不整藥物
  • 血液稀釋劑
  • 內皮素受體拮抗劑
  • 其他

第5章 全球艾森門格症候群治療市場：依通路分類，2021-2033年

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第6章 全球艾森門格症候群治療市場：依地區分類，2021-2033年

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • ASEAN
    • 澳洲
    • 韓國
    • 其他亞太國家
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲國家
  • 中東
    • GCC
    • 以色列
    • 其他中東國家
  • 非洲
    • 北非
    • 中非
    • 南非

第7章 競爭情勢

  • 公司簡介
    • Actelion Pharmaceuticals Ltd.
    • Gilead Sciences, Inc.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • AstraZeneca plc.
    • Novartis AG,
    • Merck & Co., Inc.
    • GlaxoSmithKline plc.
    • Mylan NV
    • Bayer AG.

第8章

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI1599

Eisenmenger Syndrome Treatment Market is estimated to be valued at USD 1.80 Bn in 2026 and is expected to reach USD 3.37 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.4% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 1.80 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 9.40% 2033 Value Projection: USD 3.37 Bn

The market is projected to witness significant growth due to the increasing prevalence of congenital heart diseases (CHD), rising adoption of targeted pulmonary arterial hypertension (PAH) therapies, growing awareness regarding early diagnosis, and increasing availability of specialized cardiac care facilities.

Eisenmenger syndrome is a severe cardiovascular condition that develops as a complication of untreated congenital heart defects, including ventricular septal defect (VSD), atrial septal defect (ASD), patent ductus arteriosus (PDA), and atrioventricular canal defects. The condition occurs when long-term abnormal blood flow causes progressive pulmonary vascular remodeling, resulting in pulmonary hypertension, increased pulmonary vascular resistance, and reversal of blood flow direction. This leads to reduced oxygen levels in the blood and symptoms such as cyanosis, shortness of breath, fatigue, and reduced exercise capacity.

Treatment of Eisenmenger syndrome focuses on managing symptoms, improving functional capacity, slowing disease progression, and preventing complications. Current treatment approaches include targeted pulmonary arterial hypertension therapies such as endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and prostacyclin pathway therapies, along with supportive treatments. Increasing clinical adoption of advanced PAH therapies and improvements in diagnostic technologies, including echocardiography, cardiac magnetic resonance imaging (MRI), and genetic testing, are supporting early diagnosis and treatment initiation.

The market growth is further supported by increasing investments in rare cardiovascular disease research and development activities. Pharmaceutical companies are focusing on developing advanced therapies for pulmonary hypertension and congenital heart disease-related complications. In addition, expanding access to specialized adult congenital heart disease (ACHD) centers, improving healthcare infrastructure, and updated clinical guidelines recommending specialized care are expected to support long-term market expansion.

Market Dynamics

The Eisenmenger Syndrome Treatment Market is driven by increasing congenital heart disease burden, advancements in targeted therapies, improving diagnosis rates, and growing demand for specialized cardiovascular care.

One of the primary growth drivers is the increasing prevalence of congenital heart diseases worldwide. Congenital heart defects represent one of the most common birth defects globally, and patients with untreated or late-diagnosed defects are at risk of developing Eisenmenger syndrome. The rising number of individuals surviving congenital heart defects into adulthood is increasing the demand for lifelong monitoring and advanced treatment options for associated complications.

Another major factor supporting market growth is the rising adoption of targeted pulmonary arterial hypertension therapies. Endothelin receptor antagonists, PDE-5 inhibitors, and prostacyclin-based therapies have demonstrated benefits in improving exercise capacity, reducing pulmonary vascular resistance, and managing symptoms in patients with Eisenmenger syndrome. Increasing clinical experience with combination therapies is encouraging healthcare providers to adopt personalized treatment approaches based on patient condition and disease severity.

Growing advancements in diagnostic technologies are also contributing to market expansion. Improved echocardiography, cardiac MRI, pulmonary hypertension screening, and genetic testing allow earlier detection of congenital heart abnormalities and pulmonary vascular changes. Early diagnosis enables timely intervention and improves disease management outcomes, thereby increasing demand for specialized Eisenmenger syndrome treatments.

However, the market faces challenges including limited curative treatment options, high costs associated with advanced PAH-targeted therapies, and the complex nature of disease management. Since Eisenmenger syndrome requires lifelong care and monitoring, treatment accessibility and affordability remain key concerns, particularly in developing regions. In addition, limited awareness regarding rare cardiovascular conditions may delay diagnosis and treatment initiation.

Despite these challenges, increasing investments in rare disease drug development, expansion of specialized cardiac care centers, improving healthcare access, and growing adoption of targeted combination therapies are expected to create significant growth opportunities during the forecast period.

Key Features of the Study

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study provides key insights about market drivers, restraints, opportunities, treatment trends, regional outlook, clinical advancements, and competitive strategies adopted by key players.
  • It profiles key players in the Eisenmenger Syndrome Treatment Market based on company highlights, product portfolio, key developments, financial performance, and strategies.
  • Key companies covered as a part of this study include Actelion Pharmaceuticals Ltd., Gilead Sciences, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc., Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc., Mylan N.V., and Bayer AG.
  • Insights from this report would allow pharmaceutical companies, healthcare providers, investors, and other stakeholders to make informed decisions regarding product development, market expansion, partnerships, and investment opportunities.
  • The Eisenmenger Syndrome Treatment Market report caters to various stakeholders including pharmaceutical companies, biotechnology firms, cardiologists, pulmonologists, hospitals, specialty care centers, healthcare investors, distributors, regulatory authorities, and financial analysts.
  • Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Eisenmenger Syndrome Treatment Market.

Market Segmentation

  • By Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
  • Antiarrhythmic Agents
  • Blood Thinning Agents
  • Endothelin Receptor Antagonist
  • Others
  • By Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • By Region Insights (Revenue, USD Bn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players
  • Actelion Pharmaceuticals Ltd.
  • Gilead Sciences, Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca plc.
  • Novartis AG
  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • Mylan N.V.
  • Bayer AG

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Drug Type Launches/Approvals
  • Regulatory Scenario
  • Epidemiology
  • PEST Analysis
  • Acquisition and Collaboration Scenario

4. Global Eisenmenger Syndrome Treatment Market, By Drug Type, 2021 - 2033 (USD Billion)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Antiarrhythmic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
  • Blood Thinning Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
  • Endothelin Receptor Antagonist
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)

5. Global Eisenmenger Syndrome Treatment Market, By Distribution Channel, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Billion)

6. Global Eisenmenger Syndrome Treatment Market, By Region, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, By Region, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, By Region, 2021 - 2033
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Country, 2021 - 2033, (USD Billion)
      • U.S.
      • Canada
  • Europe
    • Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Country, 2021 - 2033, (USD Billion)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Country, 2021 - 2033, (USD Billion)
      • China
      • Japan
      • India
      • ASEAN
      • Australia
      • South Korea
      • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Country, 2021 - 2033, (USD Billion)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Country, 2021 - 2033, (USD Billion)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, By Country, 2021 - 2033, (USD Billion)
      • North Africa
      • Central Africa
      • South Africa

7. Competitive Landscape

  • Company Profiles
    • Actelion Pharmaceuticals Ltd.
      • Company Overview
      • Drug Type Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Gilead Sciences, Inc.
      • Company Overview
      • Drug Type Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer, Inc.
      • Company Overview
      • Drug Type Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Overview
      • Drug Type Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • AstraZeneca plc.
      • Company Overview
      • Drug Type Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Novartis AG,
      • Company Overview
      • Drug Type Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Merck & Co., Inc.
      • Company Overview
      • Drug Type Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • GlaxoSmithKline plc.
      • Company Overview
      • Drug Type Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Mylan N.V.
      • Company Overview
      • Drug Type Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bayer AG.
      • Company Overview
      • Drug Type Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact